UNSPSC 51312102: Epinastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q13WX941EF, chemically known as 3-amino-9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepine but generally known as epinastine, which bears US NIH Compound Identifier 3241. European Medicines Agency schedules Epinastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06567MIG.

UNSPSC 51312102 Epinastine, a Commodity code, does not reflect the actual scope of state and local procurement activity tagged under it. The most recent opportunities show state and local governments soliciting naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles, not epinastine specifically. The issuing bodies range from county health departments to state HHS commissions and multi-state cooperative purchasing alliances. The work involves establishing supply agreements for pharmaceutical products to support community health initiatives, emergency response capability, and state and local government health program operations, with vendors responsible for complying with FDA requirements, cGMP certification, Drug Supply Chain Security Act compliance, and product delivery to designated facilities.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building, with a July 26, 2023 response deadline and a two-year term with optional one-year renewal. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on vendor experience with direct contracting for self-insured employers and value-based agreements. The Minnesota Department of Administration's Office of State Procurement administered MMCAP's RFP S1070000015802, posted January 2026 with a March 26, 2026 response deadline, to establish multiple contracts for generic pharmaceuticals and OTC products across state and local government facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three authorized wholesalers and meet cGMP and DSCSA compliance standards. Recent activity is concentrated in Texas, Florida, and Minnesota, with multi-state cooperative purchasing extending the geographic reach to Oregon.